The 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from June 2-6, 2017. With PD-1 therapies rapidly maturing, this year’s meeting had surprisingly little major new data from PD-1 drugs. Instead, IDO and CAR-T therapies were the featured immunotherapies with highly anticipated data from epacadostat (INCY).

To be sure, there were a number of major top-line data presentations for seemingly disparate drugs but all with the underlying theme of balancing efficacy against value. Those presentations include the APHINITY, LATITUDE, and LympiAD studies.

This post-meeting report features summaries of a few key topics along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting, for not only drugs but devices and diagnostics as well from our sister product, Meddevicetracker.


Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.